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30 Oral PresentationsHuman CD341 cells were isolated from umbilical cord blood,
stained with the membrane fluorescence marker PKH26, cultivated
in cytokine richmedia for five days and then sorted for their PKH26
fluorescence (dim versus bright, i.e. FDF versus SDF). Sorted cells
were injected into the tail vein of sublethally irradiatedNOD/SCID
mice (2  105 cells/animal). The animals were sacrificed at defined
time points from week 2 to 18 after transplantation. Flow cytomet-
ric analysis of the samples collected from the marrow, spleen, thy-
mus, and lymph nodes of the NOD/SCID mice indicated that
both SDF and FDFwere able to engraft the bone marrow of the an-
imals, i.e. erythroid and myeloid progenitor cells were recovered
from the bone marrow of SDF and FDF repopulated mice. The
most remarkable finding was that only cells of SDF origin were
found in the lymph nodes and thymus where, at week 15 they differ-
entiated into T cells. CD41CD81 double positive T progenitor
cells were recovered in the thymus and CD41 as well as CD81
T cells were present in the spleen and the lymph nodes. Until 18
weeks after reconstitution, very few B cells were present in the
spleen, whereas monocytes reached normal range. Global gene ex-
pression profiles of the two subpopulations (SDF and FDF) were
analyzed using a human transcriptome cDNA microarray. Several
molecular markers for stem cells were highly expressed in the
SDF as compared to FDF: CD133 (Prominin), MDR1 (multiple
drug resistance gene 1), clqr1 (complement component 1 receptor
1), Hoxa9, Cdx1 andHesx1 (which encode homeodomain proteins).
Our data indicated that SDF was enriched for primitive human
HSC, which were able to engraft in the thymus and lymph nodes
in the SCIDmouse model. These cells were able to give rise to pre-
cursor as well as mature T cells. Our results have provided unequiv-
ocal evidence that SDF is associated with primitive HSC function,
and is consistent with the results of differential gene expression
analysis in SDF. The significance of the cell-cell contacts in the
SCID model in maintaining stemness is currently being examined.
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TARGETING MUC1 AS A MARKER FOR MYELOID LEUKEMIA STEM CELLS
BY DC/AML FUSIONS
Rosenblatt, J.1, Wu, Z.2, Lenahan, C.1, Bissonnette, A.2, Vasir, B.2,
Miller, K.1, Joyce, R.1, Levine, J.D.1, Galinsky, I.2, Stone, R.2,
Kufe, D.2, Avigan, D.1. 1Beth Israel Deaconess Medical Center; 2Dana
Farber Cancer Institute.
The epithelial mucin antigen (MUC1) is aberrantly expressed in
many epithelial tumors and hematologic malignancies and has
served as a target for cellular immunotherapy. In this study, we ex-
aminedMUC1 as amarker formyeloid leukemia cells and their pro-
genitors. Myeloid leukemia cells were isolated from bone marrow
aspirates or peripheral blood. MUC1 was not expressed on unse-
lected leukemia cells (mean expression 3%, n 5 12). A subset of
samples underwent CD34 selection by magnetic bead separation.
In contrast to unselected cells, 38% of CD341 leukemia cells ex-
pressed MUC1 (n 5 5). The leukemia stem cell compartment was
isolated by separating CD341/CD38-/lineage- fractions by flow
cytometric sorting. Leukemia stem cells expressed MUC1 both by
immunohistochemistry and FACS analysis. Similarly, we examined
MUC1 expression on progenitor cells derived from chronic phase
CML and following blast transformation. MUC1 was seen in only
4% of CD341 cells obtained from chronic phase CML samples
(n 5 4) while uniform expression was observed in samples derived
from patients with accelerated/blast phase. These data suggest
that MUC1 serves as a marker for early leukemia progenitors and
is associated with blastic transformation. We assessed the capacity
of a dendritic cell (DC)/myeloid leukemia fusion cell vaccine to
stimulate immune responses that target MUC1 and other antigens
expressed by the stem cell compartment. DCs were generated from
adherent mononuclear cells cultured with GM-CS, IL-4 and
TNFa. DCs were fused with patient derived myeloid leukemia cells
using polyethylene glycol. Fusion cells were quantified by deter-
mining the percentage of cells that expressed unique DC and leuke-
mia antigens. Stimulation of autologous T cells with DC/AML
fusions resulted in a mean 3 fold increase in CD81 cells binding
the MUC1 tetramer (N5 4). DC/AML fusions stimulated anti-tu-
mor immune responses that targeted leukemia stem cells. Fusion
stimulated T cells demonstrated increased expression of IFNg fol-
lowing exposure to lysate generated from unselected leukemia cells(29 fold) and leukemia stem cells (28 fold). In contrast, exposure to
renal carcinoma lysate generated only a 5 fold increase in IFNg. In
summary, this data suggests that leukemic progenitors in AML and
accelerated/blast phase CML express MUC1. DC/tumor fusion
vaccines target MUC1 and the stem cell compartment, and may
be a potent immunotherapeutic strategy to eliminate the malignant
stem cell clone in AML.SUPPORTIVE CARE75
PREVENTION OF LATE CMV DISEASE AFTER HCT: A RANDOMIZED DOU-
BLE-BLIND MULTICENTER TRIAL OF VALGANCICLOVIR (VGCV) PRO-
PHYLAXIS VERSUS PCR-GUIDED GCV/VGCV PREEMPTIVE THERAPY
Boeckh, M.1, Nichols, G.1, Chemaly, R.2, Papanicolaou, G.3, Wingard, J.4,
Kirby, K.A.1, Dahlgren, C.1, Corey, L.1, Leisenring, W.1. 1Fred Hutchin-
son Cancer Research Center, Seattle, WA; 2MD Anderson Cancer Center,
Houston, TX; 3Memorial Sloan Kettering Cancer Center, New York, NY;
4University of Florida, Gainesville, FL.
Background:LateCMVdisease is an important complication af-
ter allogeneicHCT. PCR surveillance followed by preemptive ther-
apy (PET) is costly and often not feasible. VGCV prophylaxis may
prevent late CMV-related complications. Methods: Between day
80 and day 120 after HCT, CMV seropositive or D1/R- allograft
recipients with CMV infection prior to day 80 or GVHDwere ran-
domized to receive VGCV prophylaxis (900 mg/day) or placebo
(Plac) until day 270. Patients were monitored weekly for CMV
DNA by plasma PCR, blood chemistry and CBC/differential. IV
GCV (5 mg/kg twice daily) or VGCV (900 mg/kg twice daily)
was given if CMVDNA was. 1000 copies/mL. The primary end-
point was a composite of CMV disease or invasive bacterial/fungal
infection or death by day 270 and the study was designed to show
superiority of VGCV prophylaxis. Follow-up was until day 640 af-
ter HCT.Neutropenia was analyzed while receiving study drug and
by day 270. All analyses were by intent-to-treat. Results: 184 pa-
tients were randomized. All patients completed follow-up through
day 270; 84% (VGCV) and 82% (Plac) completed follow-up
through day 640 (as of 9/30/2007). There was no observed differ-
ence between the groups in the primary endpoint at day 270
(VGCV: 20%, Plac: 21%, hazard ratio [HR] 1.0, 95% CI 0.5–1.9,
P 5 0.96) and 640 (39% and 40%, HR 0.9, 95% CI 0.6–1.5, P 5
0.8). Valganciclovir prophylaxis reduced CMV PCR positivity
(11% and 36%, HR 0.3, 95% 01.-0.5, P 5 0.0002). There was
a trend towards more neutropenia on double-blind study drug (ab-
solute neutrophil count [ANC]\ 1000/mm3 43% and 29%, HR
1.7, 95%CI 0.9–2.9, P5 0.08) but no significant difference was ob-
served at day 270 (HR 1.3, 95% CI 0.8–2.1, p 5 0.21 for ANC\
1000/mm3). The number and severity of adverse events AEs (in-
cluding SAEs) was similar between the groups. There was also no
significant difference in secondary endpoints, including CMV dis-
ease at day 270 (2% in both groups, HR 0.9, 95% CI 0.1–6.5) and
640 (6% and 5%, HR 1.2, 95% CI 0.3–4.5), HSV/VZV infections
by day 640, death at any time, or relapse of the underlying disease.
Conclusion: VGCV prophylaxis was not superior in reducing the
composite endpoint of CMV disease, invasive bacterial or fungal in-
fection or death. The incidence of CMV disease was low in both
groups. VGCV reduced CMV DNAemia and the need for PET.
The rate of neutropenia and other AEs was high but not signifi-
cantly different between the groups. The study was not designed
to test for equivalency.76
AN INTERNATIONAL COMPARISON OF CURRENT STRATEGIES TO PRE-
VENT HERPESVIRUS AND FUNGAL DISEASES IN HCT RECIPIENTS
Heugel, J.1, Storek, J.2,3, Young, J.-A.3,4, Kukreja, M.3, Gress, R.3,5,
Tomblyn,M.3,4, Boeckh,M.1,3. 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Calgary, AB, Canada; 3Center for Interna-
tional Bone andMarrow Transplantation Research; 4University of Minne-
sota, Minneapolis, MN; 5National Institutes of Health, Bethesda, MD.
Oral Presentations 31Background:Little is known about the prevention practices used
by HCT centers internationally to prevent herpesvirus and fungal
infections. The purpose of this survey was to compare prevention
strategies by geographic region, center size and patient population
(pediatric vs. adult).Methods: A web-based questionnaire was dis-
tributed to Program Directors at CIBMTR-affiliated HCT centers
to elicit information on the strategies used to prevent HSV, VZV,
CMV and fungal diseases at each institution between 1999 and
2003. Results: The response rate was 80% (n 5 174) from HCT
centers in 32 countries, including the US/Canada (n5 96), Europe
(n5 40), Australia and New Zealand (n5 13), Latin America (n 5
12), Asia (n5 6), the Middle East (n5 4) and South Africa (n5 3).
While short-course acyclovir (ACV) for HSV prophylaxis was used
almost uniformly, 62% of centers routinely used prophylactic low-
dose ACV or similar agents as prophylaxis against VZV; of these,
19% treated for 1 month or less, 29% for 3–4 mos., 9% for 6–9
mos., 26% for 12 mos. and 17% until off immunosuppressants or
until immune reconstitution. Strategies to prevent CMV disease
in seropositive recipients were used in the following proportions:
high-dose ACV/VACV alone (3%), Ganciclovir-based (GCV) pro-
phylaxis alone (5%), surveillance and preemptive therapy (PET)
alone (47%) or a combination strategy (45%) most commonly
high-dose ACV and PET.The prevention strategies used in Europe
were very similar to those used in theUSwith the exception of high-
dose ACV/VACV which was used routinely by 48% of European
centers compared with 25% of US centers (P\ .05, Fisher exact
test). In Australia and NZ (grouped together), GCV prophylaxis
was used in higher proportions than in the US, Europe and Canada
(54% vs. 23%, P\ .05). Routine antifungal prophylaxis was used by
78% and 57% of European and Canadian centers, respectively,
compared with its use in the US (97%), Australia/NZ (100%),
and Latin America (100%). Also, antifungal prophylaxis was more
commonly used in pediatric centers than in adult-only centers
(97% vs 85%). Practices among smaller centers were remarkably
similar to those in high-volume centers (.50 HCTs annually).
Other trends in prevention strategies will be presented at the con-
ference. Conclusion: This large analysis sheds light on current
practices being employed globally to prevent herpesvirus and fungal
diseases in HCT recipients and highlights previously unknown dif-
ferences in prevention strategies.77
IMPACT OF RIBAVIRIN THERAPY ON RESPIRATORY SYNCITIAL VIRUS
INFECTION FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
Kodali, D., Cao, Q., Young, J., Orchard, P., Burns, L.J. University of
Minnesota, Minneapolis, MN.
Respiratory syncitial virus (RSV) infections are associated with
high morbidity and mortality among hematopoietic cell transplan-
tation (HCT) recipients. We conducted a retrospective cohort
study to determine the impact of ribavirin therapy on RSV infec-
tion, defined as respiratory symptoms with a nasopharyngeal (NP)
or bronchial lavage positive RSV assay/culture. Of 3648 HCT re-
cipients between January 1986 and August 2005, 109 (median age
32 years, range 0.6–64) were diagnosed with RSV infection; the
overall incidence was 3% (95% confidence intervals [CI], 2.5–
3.6%). Sixty-nine patients received aerosolized ribavirin therapy
(RT) and 40 did not (noRT). Median follow-up was 1.1 (range 0–
18.6) years and 4.7 (range, 0–20.0) years for the RT and noRT
groups (p 5 .01), respectively. The two groups were comparable
with respect to age, conditioning regimen, gender, donor type, un-
derlying disease, cytomegalovirus serology, transplant year, GVHD
prophylaxis and incidence, time to neutrophil recovery, NP swab
positive assay/culture and evidence of co-infections at time of diag-
nosis of RSV infection. RT patients had a shorter time from trans-
plant to RSV diagnosis (63 vs. 159 days, p\0.01), were less likely to
have neutrophil engraftment (66% vs. 85%, p 5 0.02), and were
more likely to have lower respiratory infection (LRI) as evidenced
by pulmonary infiltrates on CXR (80% vs. 27%, p\0.01). RSV in-
fection resolved in 44 patients (63%) of the RT group compared
with 37 (90%) patients in the noRT group (p 5 0.01); RSV related
deaths occurred in 15 (21%) RT patients and 1 (2%) noRT patient.
In the RT group, patients who failed therapy were more likely tohave LRI (96% vs. 68%, p\ 0.01), lack of neutrophil engraftment
(46% vs. 77%, p 5 0.01), shorter time from transplant to RSV di-
agnosis (17 days vs. 79 days, p5 0.01) and presence of co-infections
(54% vs. 16%, p\0.01).Multivariate analysis revealed the presence
of co-infections as the only predictive factor in lack of resolution of
RSV infection in the RT group (relative risk 2.54, 95% CI 1.49–
4.3). We conclude that RSV infected patients with neutrophil en-
graftment and no evidence of LRI often improve without ribavirin
therapy and can be closely monitored. In contrast, mortality re-
mains high despite ribavirin therapy in patients with LRI, lack of en-
graftment, and co-infections.78
CHRONIC HEPATITIS C, CIRRHOSIS, AND END STAGE LIVER DISEASE
AMONG 30-YEAR SURVIVORS OF BONE MARROW TRANSPLANT
Pergam, S.A.1, Strasser, S.I.2, Flowers, M.E.1, Sullivan, K.M.3,
McDonald, G.B.1. 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Sydney - AW Morrow Gastroenterology and Liver
Centre, Camperdown, Australia; 3Duke University Medical Center,
Durham, NC.
Introduction: For long-term survivors who received a bonemar-
row transplant (BMT) before the discovery of hepatitis C virus
(HCV), chronic HCV infection is a common complication. We
evaluated a cohort of BMT recipients from the pre-HCV screening
era to determine the frequency of progression to cirrhosis and End
Stage Liver Disease (ESLD) along with relevant risk factors.
Methods: We reviewed the course of a total of 134 patients trans-
planted at the Fred Hutchinson Cancer Center (FHCRC) in Seat-
tle, WA before June 1978 who survived over 10 years after BMT.
We retrospectively collected data using the FHCRC Long-Term
Follow-Up database, which includes data from periodic on-site ex-
aminations, all available outside records, laboratory tests, and yearly
questionnaires. A priori risk factors thought to be associated with
cirrhosis and ESLD were assessed using chi-squared and Wil-
coxon-rank sum analyses. Results: A total of 134 patients met cri-
teria for inclusion in the study, of which 9 were lost to follow-up,
leaving 125 evaluable patients. 82 (66%) were still alive at a median
28.6 years (24.0–35.5); 43 (34%) had died at a median 20.4 years
(10.1–31.9). HCV status was known in 94 survivors: 58 (62%)
were HCV-infected patients, of whom 7 cleared the virus. Among
51 chronically HCV-infected patients, 34 (67%) developed chronic
liver disease. Cirrhosis developed in 14/51 (27%) of these chroni-
cally infected patients, 10 of whom progressed to ESLD. Four total
ESLD patients underwent orthotopic liver transplant, 3 for decom-
pensated cirrhosis and 1 for cirrhosis with hepatocellular carcinoma
(HCC). One other patient with ESLD developed HCC. Cirrhosis
(p\0.01) and ESLD (p 5 0.02) were associated with HCV status,
but not with gender, age at transplant, diagnosis, conditioning ther-
apy, post-BMT immunosuppression, hepatitis B status, history of
graft-versus-host-disease, or history of sinusoidal obstruction syn-
drome. Conclusions: In this unique cohort of long-term survivors
of BMT with over 30 years of follow-up, a large portion of patients
were infected with HCV and most developed chronic HCV infec-
tion. Those with chronic infection are at high risk of developing cir-
rhosis and ESLD. Our data indicate that HCV infection is
a significant cause of morbidity and mortality in these patients.79
PEGFILGRASTIM (P) APPEARS TO BE EQUIVALENT TO MULTIPLE DAILY
DOSES OF FILGRASTIM (F) TO TREAT NEUTROPENIA POST-AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN PA-
TIENTS WITH NON-HODGKIN’S LYMPHOMA: RESULTS OF
A RANDOMIZED PHASE II TRIAL
Rifkin, R., Beveridge, R., Spitzer, G., Orloff, G., Mandanas, R.,
McGaughey, D., Zhan, F., Boehm, K., Asmar, L. Blood and Marrow
Transplant Network, US Oncology, Houston, TX.
Filgrastim has previously been shown to decrease the time to neu-
trophil recovery following autologous PBSCT. Therefore, it was
hypothesized that a single injection of pegfilgrastim (P) would
